content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
  <submissionType>144</submissionType>
  <filerInfo>
  <filer>
  <filerCredentials>
  <cik>0001806596</cik>
  <ccc>XXXXXXXX</ccc>
  </filerCredentials>
  </filer>
  <liveTestFlag>LIVE</liveTestFlag>
  </filerInfo>
  </headerData>
  <formData>
  <issuerInfo>
  <issuerCik>0001347178</issuerCik>
  <issuerName>Vanda Pharmaceuticals Inc.</issuerName>
  <secFileNumber>001-34186</secFileNumber>
  <issuerAddress>
  <street1 xmlns="http://www.sec.gov/edgar/common">2200 Pennsylvania Avenue NW</street1>
  <street2 xmlns="http://www.sec.gov/edgar/common">Suite 300E</street2>
  <city xmlns="http://www.sec.gov/edgar/common">Washington</city>
  <stateOrCountry xmlns="http://www.sec.gov/edgar/common">DC</stateOrCountry>
  <zipCode xmlns="http://www.sec.gov/edgar/common">20037</zipCode>
  </issuerAddress>
  <issuerContactPhone>202-734-3400</issuerContactPhone>
  <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Moran Kevin Patrick</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
  <relationshipsToIssuer>
  <relationshipToIssuer>Officer</relationshipToIssuer>
  </relationshipsToIssuer>
  </issuerInfo>
  <securitiesInformation>
  <securitiesClassTitle>Common Stock</securitiesClassTitle>
  <brokerOrMarketmakerDetails>
  <name>Merrill Lynch</name>
  <address>
  <street1 xmlns="http://www.sec.gov/edgar/common">1152 15th Street, N.W.</street1>
  <street2 xmlns="http://www.sec.gov/edgar/common">Suite 6000</street2>
  <city xmlns="http://www.sec.gov/edgar/common">Washington</city>
  <stateOrCountry xmlns="http://www.sec.gov/edgar/common">DC</stateOrCountry>
  <zipCode xmlns="http://www.sec.gov/edgar/common">20005</zipCode>
  </address>
  </brokerOrMarketmakerDetails>
  <noOfUnitsSold>27689</noOfUnitsSold>
  <aggregateMarketValue>127646.00</aggregateMarketValue>
  <noOfUnitsOutstanding>57537499</noOfUnitsOutstanding>
  <approxSaleDate>03/04/2024</approxSaleDate>
  <securitiesExchangeName>NASDAQ</securitiesExchangeName>
  </securitiesInformation>
  <securitiesToBeSold>
  <securitiesClassTitle>Common Stock</securitiesClassTitle>
  <acquiredDate>03/01/2024</acquiredDate>
  <natureOfAcquisitionTransaction>Vesting/Settlement of Restricted Stock Units</natureOfAcquisitionTransaction>
  <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
  <isGiftTransaction>N</isGiftTransaction>
  <amountOfSecuritiesAcquired>27689</amountOfSecuritiesAcquired>
  <paymentDate>03/01/2024</paymentDate>
  <natureOfPayment>Compensation</natureOfPayment>
  </securitiesToBeSold>
  <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
  <noticeSignature>
  <noticeDate>03/04/2024</noticeDate>
  <signature>/s/ Kevin Patrick Moran</signature>
  </noticeSignature>
  </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2841}]
text: 144
  0001806596
  XXXXXXXX
  LIVE
  0001347178
  Vanda Pharmaceuticals Inc.
  001-34186
  2200 Pennsylvania Avenue NW
  Suite 300E
  Washington
  DC
  20037
  202-734-3400
  Moran Kevin Patrick
  Officer
  Common Stock
  Merrill Lynch
  1152 15th Street, N.W.
  Suite 6000
  Washington
  DC
  20005
  27689
  127646.00
  57537499
  03/04/2024
  NASDAQ
  Common Stock
  03/01/2024
  Vesting/Settlement of Restricted Stock Units
  Issuer
  N
  27689
  03/01/2024
  Compensation
  Y
  03/04/2024
  /s/ Kevin Patrick Moran